|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Deoxycorticosterone [6559X]
Test Code70612
CPT Codes
82633
Preferred Specimen
3 mL serum
Minimum Volume
1.1 mL
Other Acceptable Specimens
Amniotic fluid • EDTA (lavender-top) • Sodium heparin (green-top) • PPT-potassium EDTA (white-top)
Transport Container
Red-top tube (no gel)
Transport Temperature
Refrigerated
Specimen Stability
Room temperature: 48 hours
Refrigerated: 7 days
Frozen: 2 years
Refrigerated: 7 days
Frozen: 2 years
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Received room temperature
Methodology
Extraction • Radioimmunoassay • Chromatography
Setup Schedule
Tuesday Morning; Report available: 3 Days
Reference Range
| Adult Male | 3.5-11.5 | ng/dL | |||||||||
| Adult Female | |||||||||||
| Follicular | 1.5-8.5 | ng/dL | |||||||||
| Luteal | 3.5-13.0 | ng/dL | |||||||||
| Pregnancy | |||||||||||
| First Trimester | 5-25 | ng/dL | |||||||||
| Second Trimester | 10-75 | ng/dL | |||||||||
| Third Trimester | 30-110 | ng/dL | |||||||||
| Post-ACTH Stimulation | 60 Minutes | ||||||||||
| Males and Premenopausal Females (Follicular Phase) |
14-33 | ng/dL | |||||||||
| Pediatric | |||||||||||
| ACTH Stimulation | Baseline (ng/mL) | 60 Minutes (ng/mL) | |||||||||
| <1 Year | 7-57 | 20-160 | |||||||||
| 1-5 Years | 4-49 | 26-140 | |||||||||
| 6-12 Years Male | 9-34 | 33-140 | |||||||||
| 6-12 Years Female | 2-13 | 19-61 | |||||||||
| Tanner Stages II-III | |||||||||||
| Male | 4-30 | 12-74 | |||||||||
| Female | 2-12 | 13-63 | |||||||||
| Tanner Stages IV-V | |||||||||||
| Male | 5-14 | 19-46 | |||||||||
| Female | 5-10 | 23-40 | |||||||||
Clinical Significance
DOC is a precursor of corticosterone and aldosterone.
The elevations of DOC observed in patients with
11-hydroxylase deficiency (the second leading cause of
congenital adrenal hyperplasia) may reflect the
hypertension observed. Patients with DOC-secreting
tumors also exhibit hypertension.
The elevations of DOC observed in patients with
11-hydroxylase deficiency (the second leading cause of
congenital adrenal hyperplasia) may reflect the
hypertension observed. Patients with DOC-secreting
tumors also exhibit hypertension.
